Immune Design Garners $49,000,000 Series C Financing

  • Feed Type
  • Date
    10/30/2013
  • Company Name
    Immune Design
  • Mailing Address
    1616 Eastlake Ave. E. Seattle, WA 98102
  • Company Description
    One of the greatest impacts on human health can be achieved by regulating the activity of the immune system. Recent advances in the field of molecular immunology have created new ways to treat infectious disease, cancer, allergy and autoimmunity. We are using this knowledge to discover and develop therapeutics that will protect and save lives world-wide.
  • Website
    http://www.immunedesign.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $49,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The funds will be used primarily to advance Immune Design’s cancer immunotherapy product pipeline, including proof-of-concept studies for its lead therapeutic candidates ID-LV305 and ID-G305.
  • M&A Terms
  • Venture Investor
    The Column Group
  • Venture Investor
    Topspin Partners
  • Venture Investor
    Alta Partners
  • Venture Investor
    Versant Ventures
  • Venture Investor
    ProQuest Investments
  • Venture Investor
    Osage Partners
  • Venture Investor
    Sanofi-Genzyme BioVentures

By posting a comment, you agree to our terms and conditions.